It is important to recognize FGF23-mediated persistent hypophosphatemia and its associated osteomalacia, irrespective of PHEX gene status, as it may be effectively managed with burosumab regardless of its underlying etiology. The gene discussed is FGF23; the disease is osteomalacia.